HOME >> BIOLOGY >> NEWS
Scripps scientists say genetic mutation doesn't protect against HIV and plague

A group of scientists at The Scripps Research Institute have provided strong evidence that a popular hypothesis concerning the origins of a genetic mutation common among Caucasians of Northern European descent that protects against human immunodeficiency virus (HIV) is wrong.

The hypothesis suggests that the mutation conferred resistance against bubonic plague in the Middle Ages, much as it does against HIV today. This idea was based on the fact that the mutation first appeared around the same time that the "Black Death" plague epidemic killed a third of Europe's population in the years 1346-1352. Since HIV was not present in Europe at this time, individuals with the mutation must have been protected against some other disease.

In a brief communication to be published this week in the journal Nature, Scripps Research Immunology Professor Donald Mosier and his colleagues show this hypothesis to be incorrect.

Mosier performed studies that demonstrate that the mutation does not protect against plague infection in mouse models and that it is unlikely to have offered any protection against the plague in humans during the Middle Ages.

An Important Receptor

The mutation in question is in the C-C chemokine receptor 5 gene, which makes the human receptor protein called CCR5. CCR5 is a seven trans-membrane spanning protein of 332 amino acids that inserts into the cell membranes of human CD4+ T helper cells. HIV particles use CCR5 to gain entry into CD4+ T cells.

The CCR5 32 mutation -- a deletion of 32 bases of DNA from the CCR5 gene -- was first identified in 1996 in individuals who seemed to be protected from infection with HIV despite having had multiple high-risk exposures to the virus.

The resistant individuals all had the 32-base pair mutation in their CCR5 genes, and that left them with CD4+ T cells with no CCR5 receptors, conferring resistance to HIV infection. Later data showed that individua
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
11-Feb-2004


Page: 1 2

Related biology news :

1. Structure solved at Scripps shows how one human protein reduces potency of chemotherapy
2. Protein believed to control formation of memory identified by Scripps & UCSD scientists
3. 22-amino acid bacterium created by Scripps scientists
4. Scripps scientists look deep inside sharks and their high-performance swimming system
5. Scripps research scientist wins 2004 Koch Prize
6. Scripps Research scientists find deafness genes function
7. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
8. Scripps scientists describe dangerous cocktail of alcohol, brain peptides, and neurotransmitters
9. Chemical that turns mouse stem cells into heart muscles discovered by Scripps researchers
10. Structure solved by Scripps scientists shows one way that body controls gene expression
11. Scientists at Scripps Research Institute describe structure of receptor on surface of 1918 flu virus

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... 01, 2020 , ... Catalent, a global leader in clinical ... packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating ... the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... for biopharmaceutical R&D, today announced that it has entered into a multi-year ... antibodies (Multiclonics®), to support their translational and clinical research strategy to discover ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
(Date:7/18/2020)... ... 2020 , ... dicentra , a leading Contract Research ... is pleased to announce that Charles Galea has joined its clinical trials division ... an accomplished and results-driven sales executive with over 10 years of expertise in ...
(Date:7/10/2020)... ... July 09, 2020 , ... In most ... used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate ... Dr MA has been using the zebrafish model to investigate the causes of ...
(Date:7/7/2020)... BOSTON (PRWEB) , ... July 06, 2020 , ... ... Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of ... Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples ...
Breaking Biology Technology:
Cached News: